DOCSLIB.ORG

Clinical Review Fadi Nossair Efficacy Supplement – S-041 Pradaxa – Dabigatran Etexilate

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Clinical Review Fadi Nossair Efficacy Supplement – S-041 Pradaxa – Dabigatran Etexilate Clinical Review Fadi Nossair Efficacy Supplement – S-041 Pradaxa – dabigatran etexilate CLINICAL AND STATISTICAL REVIEW Application Type Efficacy Supplement Application Number(s) sNDA 022512, S-0041; (b) (4) NDA 214358 Priority or Standard Priority Submit Date(s) 9/21/2020 Received Date(s) 9/21/2020 PDUFA Goal Date 3/21/2021 Division/Office Division of Non-malignant Hematology (DNH) Reviewer Name(s) Fadi Nossair CDTL Name Virginia Kwitkowski Statistical Reviewer Sarabdeep Singh Statistical Team Leader Yeh-Fong Chen Review Completion Date 2/23/2021 Established/Proper Name Pradaxa® (Proposed) Trade Name Dabigatran etexilate Applicant Boehringer Ingelheim Pharmaceuticals, Inc. Dosage Form(s) Capsule, oral pellets, (b) (4) Applicant Proposed Dosing Twice-daily oral administration of actual weight-based and age-based Regimen(s) dosing Applicant Proposed For sNDA 022512, S-0041: Indication(s)/Population(s) - For the treatment of venous thromboembolism in pediatric patients 8 years of age and older who have been treated with parenteral anticoagulants for at least 5 days - To reduce the risk of recurrence of venous thromboembolism in pediatric patients 8 years of age and older who have been previously treated (b) (4) For NDA 214358: - For the treatment of venous thromboembolism in pediatric patients (b) (4) 12 years of age who have been treated with parenteral anticoagulants for at least 5 days - To reduce the risk of recurrence of venous thromboembolism in pediatric patients (b) (4) 12 years of age who have been previously treated 1 Reference ID: 4751663 Clinical Review Fadi Nossair Efficacy Supplement – S-041 Pradaxa – dabigatran etexilate Recommendation on Traditional Approval for sNDA 022512, S-004 and NDA 214358 Regulatory Action (b) (4) Recommended For sNDA 022512, S-0041: Indication(s)/Population(s) - For the treatment of venous thromboembolism in adult and (if applicable) pediatric patients 8 years of age and older who have been treated with parenteral anticoagulants for at least 5-10 days - To reduce the risk of recurrence of venous thromboembolism in adult and pediatric patients 8 years of age and older who have been previously treated NDA 214358 (for Pradaxa oral pellets): - For the treatment of venous thromboembolism in pediatric patients (b) (4) to less than 12 years of age who have been treated with parenteral anticoagulants for at least 5 days. - To reduce the risk of recurrence of venous thromboembolism in pediatric patients (b) (4) to less than 12 years of age who have been previously treated. 2 Reference ID: 4751663 Clinical Review Fadi Nossair Efficacy Supplement – S-041 Pradaxa – dabigatran etexilate Table of Contents Glossary ..........................................................................................................................................8 1. Executive Summary...............................................................................................................10 1.1. Product Introduction......................................................................................................10 1.2. Conclusions on the Substantial Evidence of Effectiveness.............................................11 1.3. Benefit-Risk Assessment ................................................................................................12 1.4. Patient Experience Data.................................................................................................18 2. Therapeutic Context..............................................................................................................19 2.1. Analysis of Condition......................................................................................................19 2.2. Analysis of Current Treatment Options .........................................................................20 3. Regulatory Background .........................................................................................................24 3.1. U.S. Regulatory Actions and Marketing History.............................................................24 3.2. Summary of Presubmission/Submission Regulatory Activity ........................................25 3.3. Foreign Regulatory Actions and Marketing History .......................................................26 4. Significant Issues from Other Review Disciplines Pertinent to Clinical Conclusions on Efficacy and Safety ................................................................................................................27 4.1. Office of Scientific Investigations (OSI) ..........................................................................27 4.2. Product Quality ..............................................................................................................27 4.3. Nonclinical Pharmacology/Toxicology ...........................................................................32 4.4. Clinical Pharmacology ....................................................................................................33 4.5. Consumer Study Reviews...............................................................................................34 5. Sources of Clinical Data and Review Strategy .......................................................................36 5.1. Table of Clinical Studies .................................................................................................36 5.2. Review Strategy .............................................................................................................39 6. Review of Relevant Individual Trials Used to Support Efficacy .............................................41 6.1. Trial 1160.106 ................................................................................................................41 6.1.1. Study Design ...........................................................................................................41 6.1.2. Study Results ..........................................................................................................52 6.2. Trial 1160.108 ................................................................................................................66 3 Reference ID: 4751663 Clinical Review Fadi Nossair Efficacy Supplement – S-041 Pradaxa – dabigatran etexilate 6.2.1. Study Design ...........................................................................................................66 6.2.2. Study Results ..........................................................................................................73 7. Integrated Review of Effectiveness.......................................................................................81 8. Review of Safety....................................................................................................................81 8.1. Safety Review Approach ................................................................................................81 8.2. Review of the Safety Database ......................................................................................83 8.2.1. Overall Exposure.....................................................................................................83 8.2.2. Relevant characteristics of the safety population: .................................................86 8.2.3. Adequacy of the safety database: ..........................................................................86 8.3. Adequacy of Applicant’s Clinical Safety Assessments....................................................87 8.3.1. Issues Regarding Data Integrity and Submission Quality........................................87 8.3.2. Categorization of Adverse Events...........................................................................87 8.3.3. Routine Clinical Tests..............................................................................................88 8.4. Safety Results.................................................................................................................89 8.4.1. Deaths.....................................................................................................................89 8.4.2. Serious Adverse Events...........................................................................................91 8.4.3. Dropouts and/or Discontinuations Due to Adverse Effects....................................92 8.4.4. Significant Adverse Events......................................................................................93 8.4.5. Treatment Emergent Adverse Events and Adverse Reactions ...............................93 8.4.6. Laboratory Findings ................................................................................................99 8.4.7. Vital Signs..............................................................................................................100 8.4.8. Electrocardiograms (ECGs) ...................................................................................100 8.5. Analysis of Submission-Specific Safety Issues..............................................................100 8.6. Safety Analyses by Demographic Subgroups ...............................................................100 8.7. Specific Safety Studies/Clinical Trials ...........................................................................101 8.8. Additional Safety Explorations.....................................................................................101 8.8.1. Human Carcinogenicity or Tumor Development ..................................................101 8.8.2. Human Reproduction and Pregnancy...................................................................101
Load more

Recommended publications
  • Table of Contents
    Table of Contents 1 Signs and Symptoms 1. Chest Pain ��������������������������������������������������������������������������������������������������������49 2. Constipation �����������������������������������������������������������������������������������������������������49 3. Cough ���������������������������������������������������������������������������������������������������������������54 4. Cyanosis �����������������������������������������������������������������������������������������������������������58 5. Diarrhea �����������������������������������������������������������������������������������������������������������59 6. Dyspepsia ���������������������������������������������������������������������������������������������������������66 7. Dysphagia ���������������������������������������������������������������������������������������������������������67 8. Dyspnea: General Considerations ��������������������������������������������������������������������69 9. Edema ��������������������������������������������������������������������������������������������������������������72 10. Fever of Unknown Origin ���������������������������������������������������������������������������������74 11. Fingers, Deformed ��������������������������������������������������������������������������������������������77 11.1. Clubbing ��������������������������������������������������������������������������������������������������77 11.2. Fingers in Rheumatic Diseases ���������������������������������������������������������������78
    [Show full text]
  • Paradoxical Embolism: Role of Imaging in Diagnosis and Treat- Ment Planning1
    Note: This copy is for your personal non-commercial use only. To order presentation-ready copies for distribution to your colleagues or clients, contact us at www.rsna.org/rsnarights. PARADOXICAL EMBOLISM PARADOXICAL 1571 Paradoxical Embolism: Role of Imaging in Diagnosis and Treat- ment Planning1 Farhood Saremi, MD Neelmini Emmanuel, MD Paradoxical embolism (PDE) is an uncommon cause of acute Philip F. Wu, BS arterial occlusion that may have catastrophic sequelae. The pos- Lauren Ihde, MD sibility of its presence should be considered in all patients with an David Shavelle, MD arterial embolus in the absence of a cardiac or proximal arterial John L. Go, MD source. Despite advancements in radiologic imaging technology, Damián Sánchez-Quintana, MD, PhD the use of various complementary modalities is usually necessary to exclude other possibilities from the differential diagnosis and Abbreviations: DVT = deep venous thrombo- achieve an accurate imaging-based diagnosis of PDE. In current sis, IVC = inferior vena cava, PDE = paradoxical embolism, PFO = patent foramen ovale practice, the imaging workup of a patient with symptoms of PDE usually starts with computed tomography (CT) and magnetic RadioGraphics 2014; 34:1571–1592 resonance (MR) imaging to identify the cause of the symptoms Published online 10.1148/rg.346135008 and any thromboembolic complications in target organs (eg, Content Codes: stroke, peripheral arterial occlusion, or visceral organ ischemia). 1From the Departments of Radiology (F.S., Additional imaging studies with modalities such as peripheral N.E., P.F.W., L.I., J.L.G.) and Cardiovascular venous Doppler ultrasonography (US), transcranial Doppler US, Medicine (D.S.), University of Southern Califor- echocardiography, and CT or MR imaging are required to detect nia, USC University Hospital, 1500 San Pablo St, Los Angeles, CA 90033; and Department of peripheral and central sources of embolism, identify cardiac and/ Human Anatomy, University of Extremadura, or extracardiac shunts, and determine whether arterial disease is Badajoz, Spain (D.S.Q.).
    [Show full text]
  • Successful Innominate Thromboembolectomy of a Paradoxic Embolus
    Successful innominate thromboembolectomy of a paradoxic embolus Robert G. Turnbull, MD, Victor T. Tsang, MD, Philip A. Teal, MD, and Anthony J. Salvian, MD, Vancouver, British Columbia, Canada A 54 year-old man had symptoms of acute right hemispheric cerebral ischemia. He was initially considered for participation in a trial of early thrombolysis in stroke, but an innominate artery embolus was found with no apparent arterial source. The embolus was removed by means of a combined brachial and carotid bifurcation approach to pro- tect the cerebral vasculature from embolic fragmentation during extraction. Further investigation revealed deep venous thrombosis, evidence of pulmonary emboli, and a patent foramen ovale, supporting a diagnosis of paradoxic embolus. Additional treat- ment included anticoagulation and placement of an inferior vena caval filter. The unusu- al condition of paradoxic embolus is reviewed, and the management of this patient is dis- cussed. (J Vasc Surg 1998;28:742-5.) Paradoxic embolus involves passage of a venous tone, visual field deficit, and hyperreflexia in keeping with embolus into the arterial system. Although the exis- a right-hemispheric stroke. The patient also had a cold, tence of this clinical event has been established for pulseless right arm. Cuff blood pressure was obtainable many years, advances in our ability to diagnose only from the left arm, which was normal to examination. intracardiac right-to-left shunts has increased recog- There also was no right carotid impulse. An electrocardiogram showed normal sinus rhythm nition of the potential for paradoxic emboli to occur. with old nonspecific anteroinferior T-wave changes. A Still, management and prevention of this problem computed tomographic scan of the head showed no evi- are controversial.
    [Show full text]
  • Diagnosis and Treatment of Pulmonary Arteriovenous Malformations In
    Diagnostic and Interventional Imaging (2013) 94, 835—848 REVIEW / Thoracic imaging Diagnosis and treatment of pulmonary arteriovenous malformations in hereditary hemorrhagic telangiectasia: An overview ∗ P. Lacombe, A. Lacout , P.-Y. Marcy, S. Binsse, J. Sellier, M. Bensalah, T. Chinet, I. Bourgault-Villada, S. Blivet, J. Roume, G. Lesur, J.-H. Blondel, C. Fagnou, A. Ozanne, S. Chagnon, M. El Hajjam Radiology department, Pluridisciplinary HHT team, Ambroise-Paré Hospital, Groupement des Hôpitaux Île-de-France Ouest, Assistance Publique—Hôpitaux de Paris, Université de Versailles-Saint-Quentin-en-Yvelines, 9, avenue Charles-de-Gaulle, 92100 Boulogne-Billancourt, France KEYWORDS Abstract Hereditary hemorrhagic telangiectasia (HHT) or Rendu-Osler-Weber disease is an Hereditary autosomic dominant disorder, which is characterized by the development of multiple arteriove- hemorrhagic nous malformations in either the skin, mucous membranes, and/or visceral organs. Pulmonary telangiectasia; arteriovenous malformations (PAVMs) may either rupture, and lead to life-threatening hemopt- Rendu-Osler disease; ysis/hemothorax or be responsible for a right-to-left shunting leading to paradoxical embolism, Pulmonary causing stroke or cerebral abscess. PAVMs patients should systematically be screened as the arteriovenous spontaneous complication rate is high, by reaching almost 50%. Neurological complications rate malformations; is considerably higher in patients presenting with diffuse pulmonary involvement. PAVM diagno- Percutaneous sis is mainly based upon transthoracic contrast echocardiography and CT scanner examination. embolization; The latter also allows the planification of treatments to adopt, which consists of percutaneous Right-to-left shunt embolization, having replaced surgery in most of the cases. The anchor technique consists of percutaneous coil embolization of the afferent pulmonary arteries of the PAVM, by firstly pla- cing a coil into a small afferent arterial branch closely upstream the PAVM.
    [Show full text]
  • Pdf 497.23 K
    Iran Prevalence of Cardiac Risk Factors in Ischemic Stroke in a University Medical Center in Tehran Mostafavi A, et al. ian Heart Journal; 201 Original Article Prevalence of Cardiac Risk Factors in Ischemic Stroke in a University Medical Center in Tehran Mostafavi et al. Prevalence of Cardiac Risk Factors in Ischemic Stroke in a University Medical Center in Tehran 6 ; 1 1 17 Atoosa Mostafavi , MD; Pooria Sekhavatfar , MD; ( 1 Seyed Abdolhussein Tabatabaei*1, MD; Siamak Khavandi1, MD; ) Seyedehsahel Rasoulighasemlouei1, MD ABSTRACT Background: The relative importance of different risk factors of stroke may vary between various etiologies and countries. We sought to describe the cardiac risk factors of ischemic cerebral infarction in a university hospital in Tehran, Iran. Methods: This prospective, observational study was carried out on 58 consecutive patients admitted to the neurology ward of Baharloo Hospital in Tehran, Iran, with a diagnosis of established ischemic stroke or transient ischemic attack. Data regarding each patient’s demographic profile, clinical presentation, medical history (emphasis on risk factors), results of brain imaging, biochemical profile, and other diagnostic tests were recorded in a structured form. Diagnostic neurological studies comprised computed tomography scan of the head and brain, brain magnetic resonance imaging in selected patients, and Doppler ultrasonography of carotid arteries. Cardiologic studies consisted of standard 12-lead ECG, 24-hour Holter monitoring, and 2D transesophageal echocardiography (TEE) obtained over a 7-day period after the onset of symptoms. The recorded data were statistically analyzed for the percent- age, mean, and standard deviation of all the variables. SPSS, version 22.0, for Windows was used for all the statistical analyses.
    [Show full text]
  • Simultaneous Multifocal Paradoxical Embolism in an Elderly Patient with Patent Foramen Ovale: a Case Report
    Open Access Case Report DOI: 10.7759/cureus.6992 Simultaneous Multifocal Paradoxical Embolism in an Elderly Patient with Patent Foramen Ovale: A Case Report Hassan M. Lak 1 , Taha Ahmed 2 , Raunak Nair 1 , Anjli Maroo 3 1. Internal Medicine, Cleveland Clinic - Fairview Hospital, Cleveland, USA 2. Internal Medicine, Cleveland Clinic Foundation, Cleveland, USA 3. Cardiology, Cleveland Clinic - Fairview Hospital, Cleveland, USA Corresponding author: Hassan M. Lak, [email protected] Abstract About one-third of ischemic strokes may be associated with a patent foramen ovale (PFO). This article presents an unusual case of a 68-year-old woman with simultaneous paradoxical thrombo-embolization to different systemic sites. The patient presented initially with visual deficits and intracerebellar hemorrhage but was found to have concomitant saddle pulmonary embolism, sub-acute cerebral infarction with focal neurological deficits, and thromboembolism to the superior mesenteric artery (SMA) that resulted in an ischemic bowel. The unifying diagnosis was paradoxical embolism through a PFO and an atrial septal aneurysm with high-risk features. The patient underwent percutaneous closure of the PFO with an Amplatzer device. Categories: Cardiology, Internal Medicine, Pulmonology Keywords: pfo, saddle, embolism, amplatzer Introduction Paradoxical embolism (PDE) or crossed embolism refers to an embolus of venous origin which is carried directly into the arterial circulatory system, or vice versa through a right to left intracardiac shunt such as a patent foramen ovale (PFO) [1]. In about 25% of people, the foramen ovale fails to close properly after birth, leaving them with a PFO. PFO is usually asymptomatic; however, it may play a role in the development of a cryptogenic stroke (CS).
    [Show full text]
  • Postcesarean Pulmonary Embolism, Sustained Cardiopulmonary
    Case Reports Postcesarean Pulmonary ducted a systematic, all-language literature review using Ovid (MEDLINE, Fulltext, and Cochrane), Embolism, Sustained Inspire, MD Consult, and UpToDate search engines, Cardiopulmonary Resuscitation, and other expert search strategies, from 1966 to Embolectomy, and Near-Death December 2004. Experience CASE Alan T. Marty, MD, Frank L. Hilton, MD, Under epidural anesthesia a 31-year-old G2, P2, Ab0 woman underwent a repeat cesarean delivery and delivered a Robert K. Spear, MD, and Bruce Greyson, MD 3.178-kg male infant. She had no complications until 1040 the next morning when she collapsed after standing up. Her BACKGROUND: Survival after surgical embolectomy for blood pressure initially was unobtainable and then rose to 50 massive postcesarean pulmonary embolism causing sus- to 60 mm Hg systolic. Her pulse rate was 130 to 140; she tained cardiac arrest is rare. appeared breathless and complained of substernal chest pain. CASE: One day after an uneventful cesarean delivery, a Her nail beds were blue. She was alert, cooperative, and woman developed cardiac asystole and apnea due to anxious. Breath sounds were equal on both sides of the chest. pulmonary embolism. Femoral-femoral cardiopulmonary Oxygen, intravenous fluids, heparin, and dopamine were bypass performed during continuous cardiopulmonary administered, but her blood pressure remained at 60 mm Hg. resuscitation allowed a successful embolectomy. Upon An electrocardiogram showed severe right-axis devia- awakening, the patient reported a near-death experi- tion. A radial arterial line was placed and a pulmonary ence. Pulmonary embolism causes approximately 2 arteriogram was performed. During the pulmonary angio- deaths per 100,000 live births per year in the United gram, which showed bilateral pulmonary emboli with States, and postcesarean pulmonary embolism is proba- complete obstruction of the right pulmonary artery and bly more common than pulmonary embolism after vag- essentially complete obstruction of the left pulmonary inal delivery.
    [Show full text]
  • 47-Management-Stroke-Infants-And
    Management of Stroke in Infants and Children : A Scientific Statement From a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young E. Steve Roach, Meredith R. Golomb, Robert Adams, Jose Biller, Stephen Daniels, Gabrielle deVeber, Donna Ferriero, Blaise V. Jones, Fenella J. Kirkham, R. Michael Scott and Edward R. Smith Stroke 2008, 39:2644-2691: originally published online July 17, 2008 doi: 10.1161/STROKEAHA.108.189696 Stroke is published by the American Heart Association. 7272 Greenville Avenue, Dallas, TX 72514 Copyright © 2008 American Heart Association. All rights reserved. Print ISSN: 0039-2499. Online ISSN: 1524-4628 The online version of this article, along with updated information and services, is located on the World Wide Web at: http://stroke.ahajournals.org/content/39/9/2644 An erratum has been published regarding this article. Please see the attached page for: http://stroke.ahajournals.org/http://stroke.ahajournals.org/content/40/1/e8.full.pdf Data Supplement (unedited) at: http://stroke.ahajournals.org/content/suppl/2008/09/23/STROKEAHA.108.189696.DC1.html Subscriptions: Information about subscribing to Stroke is online at http://stroke.ahajournals.org//subscriptions/ Permissions: Permissions & Rights Desk, Lippincott Williams & Wilkins, a division of Wolters Kluwer Health, 351 West Camden Street, Baltimore, MD 21202-2436. Phone: 410-528-4050. Fax: 410-528-8550. E-mail: [email protected] Reprints: Information about reprints can be found online at http://www.lww.com/reprints Downloaded from http://stroke.ahajournals.org/ by guest on November 14, 2011 AHA Scientific Statement Management of Stroke in Infants and Children A Scientific Statement From a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young E.
    [Show full text]
  • Stroke and Migraine Is There a Possible Comorbidity?
    Spalice et al. Italian Journal of Pediatrics (2016) 42:41 DOI 10.1186/s13052-016-0253-8 REVIEW Open Access Stroke and migraine is there a possible comorbidity? Alberto Spalice*, Francesca Del Balzo, Laura Papetti, Anna Maria Zicari, Enrico Properzi, Francesca Occasi, Francesco Nicita and Marzia Duse Abstract The association between migraine and stroke is still a dilemma for neurologists. Migraine is associated with an increased stroke risk and it is considered an independent risk factor for ischaemic stroke in a particular subgroup of patients. The pathogenesis is still unknown even if several studies report some common biochemical mechanisms between these two diseases. A classification of migraine-related stroke that encompasses the full spectrum of the possible relationship between migraine and stroke includes three main entities: coexisting stroke and migraine, stroke with clinical features of migraine, and migraine-induced stroke. The concept of migraine-induced stroke is well represented by migrainous infarction and it is described in the revised classification of the International Headache Society (IHS), representing the strongest demonstration of the relationship between ischaemic stroke and migraine. A very interesting common condition in stroke and migraine is patent foramen ovale (PFO) which could play a pathogenetic role in both disorders. The neuroradiological evidence of subclinical lesions most typical in the white matter and in the posterior artery territories in patients with migraine, opens a new field of research. In conclusion the association between migraine and stroke remains an open question. Solving the above mentioned issues is fundamental to understand the epidemiologic, pathogenetic and clinical aspects of migraine-related stroke.
    [Show full text]
  • Paradoxical Embolism with Thrombus Stuck in a Patent Foramen Ovale: a Review of Treatment Strategies
    European Review for Medical and Pharmacological Sciences 2018; 22: 8885-8890 Paradoxical embolism with thrombus stuck in a patent foramen ovale: a review of treatment strategies A. MIRIJELLO1, M.M. D’ERRICO1, S. CURCI1, P. SPATUZZA2, D. GRAZIANO1, M. LA VIOLA1, V. D’ALESSANDRO1, M. GRILLI1, G. VENDEMIALE3, M. CASSESE2, S. DE COSMO1 1Department of Medical Sciences, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy 2Department of Cardiovascular Sciences, Cardiac Surgery Unit, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy 3Internal Medicine and Geriatrics Residency School, University of Foggia, Foggia, Italy Antonio Mirijello and Maria Maddalena D’Errico equally contributed to the manuscript Abstract. – OBJECTIVE: Paradoxical embo- Introduction lism represents a rare condition occurring when a thrombus originating from venous system pro- Paradoxical embolism is defined as a ve- duces pulmonary embolism and systemic em- nous thrombosis producing systemic embolism bolization through an intracardiac or pulmonary 1 shunt. The evidence of a thrombus entrapped in through an intracardiac or pulmonary shunt . a patent foramen ovale (PFO) is an even more ra- The most common cause of intracardiac shunt is re condition. There is uncertainty about the op- represented by patent foramen ovale (PFO). This timal treatment strategy. last can be found in about a quarter of the adult PATIENTS AND METHODS: A 58-year-old population2 and it is generally asymptomatic3. male patient was admitted to our Internal Medi- However, it could predispose to cryptogenic cine Unit with the diagnosis of bilateral broncho- stroke4 due to systemic embolism. On the con- pneumonia. During hospitalization, the co-oc- currence of chest pain and amaurosis led us to trary, the exact incidence of paradoxical embo- hypothesize a paradoxical embolism.
    [Show full text]
  • Paradoxical Emboli from Calf and Pelvic Veins in Cryptogenic Stroke
    UC Irvine UC Irvine Previously Published Works Title Paradoxical emboli from calf and pelvic veins in cryptogenic stroke. Permalink https://escholarship.org/uc/item/70x2n594 Journal Journal of neuroimaging : official journal of the American Society of Neuroimaging, 13(3) ISSN 1051-2284 Authors Cramer, Steven C Maki, Jeffrey H Waitches, Gayle M et al. Publication Date 2003-07-01 DOI 10.1111/j.1552-6569.2003.tb00181.x License https://creativecommons.org/licenses/by/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California 10.1177/1051228403254642 Journal of Neuroimaging Vol 13 No 3 July 2003 Cramer et al: DVT in Cryptogenic Stroke ARTICLE Clinical Investigative Studies Paradoxical Emboli From Calf Steven C. Cramer, MD and Pelvic Veins in Jeffrey H. Maki, MD, PhD Cryptogenic Stroke Gayle M. Waitches, DO Neisha D’Souza James C. Grotta, MD W. Scott Burgin, MD Larry A. Kramer, MD ABSTRACT of the 10 did have clinical conditions suggesting predisposition to developing DVTs, such as concomitant neoplasms or pulmo- Purpose. The increased prevalence of patent foramen ovale in nary embolism. Conclusions. Increased evidence for paradoxi- patients with cryptogenic strokes suggests the occurrence of cal embolism may emerge when diagnostic strategies use multi- paradoxical embolism. The identification of deep venous ple imaging methods and evaluate a broad extent of the thromboses (DVTs) in this population would strengthen this subdiaphragmatic veins. hypothesis. The purpose of this study was to image the subdiaphragmatic venous system in a cohort of patients with Key words: Cryptogenic stroke, paradoxical embolism, deep cryptogenic strokes. Materials and Methods.
    [Show full text]
  • Paradoxical Coronary Artery Embolism ‑ a Rare Cause of Myocardial Infarction
    [Downloaded free from http://www.heartviews.org on Thursday, April 02, 2015, IP: 197.35.205.244] || Click here to download free Android application for this journal Case Report Paradoxical Coronary Artery Embolism ‑ A Rare Cause of Myocardial Infarction Fayaz A. Hakim, Evan P. Kransdorf, Muaz M. Abudiab, John P. Sweeney Department of Medicine, Division of Cardiovascular Diseases, Mayo Clinic, Scottsdale, Arizona, USA ABSTRACT Paradoxical coronary artery embolism is a rare, but often an underdiagnosed cause of acute myocardial infarction. It should be considered in patient who presents with chest pain and otherwise having a low risk profile for atherosclerosis coronary artery disease. We describe a case of paradoxical coronary artery embolism causing ST segment elevation myocardial infarction in a patient with upper extremity venous thrombosis. Echocardiography demonstrated a patent foramen ovale (PFO) with bidirectional shunt. In addition to treatment of acute coronary event closure of the PFO should be considered to prevent a recurrence. Key words: Coronary artery, embolism, flush occlusion, myocardial infarction, paradoxical How to cite this article: Hakim FA, Kransdorf EP, Abudiab MM, Sweeney JP. Paradoxical coronary artery embolism - A rare cause of myocardial infarction. Heart Views 2014;15:124-6. © Gulf Heart Association 2014. INTRODUCTION elevation in inferior (II, III, and aVF) leads. Cardiac biomarkers were elevated (Troponin-T 2.230 ng/ml oronary artery embolism is an established (normal <0.01 ng/ml) and creatine kinase myocardial cause of acute coronary syndrome, but band fraction 65.1 ng/ml (normal <6.7 ng/ml)). Coronary Cparadoxical coronary artery embolism causing angiography revealed flush occlusion of the posterior myocardial infarction is rare and requires a high descending artery and posterolateral branch of the degree of clinical suspicion for diagnosis.
    [Show full text]